Statin use and delayed onset of Huntington’s disease.
Schultz JL, Nopoulos PC, Killoran A, Kamholz JA.
Mov Disord 2019; 34:281-285.
There is evidence to suggest that 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitors (statins) may be beneficial in Huntington’s disease (HD).
This study aimed to determine if statin use was associated with delayed motor diagnosis in participants with premotor HD.
Among premotor HD participants from the Enroll-HD database, statin users were propensity score matched with statin nonusers based on cytosine-adenine-guanine-age product score, cytosine-adenine-guanine repeat length, baseline age, sex, and region. A Cox regression survival analysis compared the annualized hazard ratio (HR) of receiving a motor diagnosis between the 2 groups.
The annualized HR of progressing to an HD motor diagnosis was lower in the statin users (n = 89) when compared with the statinnonusers (n = 89; HR = 0.27 [95% CI 0.18-0.50], P < .0001).
In patients with premotor HD, statin use was associated with a delayed motor diagnosis of HD. Further studies are warranted to investigate if statins would be an effective disease-modifying therapy for HD.